Cystic fibrosis (CF) is a genetic disease affecting approximately 30,000 children and adults in the United States.

CF causes the body to produce abnormally thick, sticky mucus within the cells that line organs, such as the lungs and pancreas. This mucus accumulates in the lungs, enhancing the potential for infection. In the pancreas, this mucus obstructs enzyme movement to the intestines where they are needed to help break down and digest food. Effective enzyme-replacement therapy is necessary to compensate for this pancreatic insufficiency.

CF clinicians have grown accustomed to and continue to demand only the highest-quality pancreatic enzymes for their patients.

The introduction of the Pangestyme™ line of enteric-coated pancreatic enzymes to the marketplace in the fall of 2000 has represented a unique opportunity to showcase the best of our parent company's drug-delivery technology capabilities.

Pangestyme™ is the first full line of high-quality, delayed-release Pancrelipase capsules that are manufactured, inspected, and packaged in the United States without the use of organic solvents in their enteric coating.